TY - JOUR
T1 - Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions
AU - Kelbæk, Henning
AU - Yeh, Robert W
AU - Engstrøm, Thomas
AU - Neumann, Franz-Josef
AU - Serruys, Patrick W
AU - Windecker, Stephan
AU - Belardi, Jorge
AU - Qiao, Shubin
AU - Xu, Bo
AU - Liu, Minglei
AU - Silber, Sigmund
PY - 2021/3/19
Y1 - 2021/3/19
N2 - AIMS: Reports of long-term outcomes of patients treated with drug-eluting stents in total coronary occlusions are limited. We analyzed clinical outcomes of patients treated with the zotarolimus-eluting Resolute stent (R-ZES) implanted in total coronary versus non-occluded lesions.METHODS AND RESULTS: Patients treated with R-ZES and included in 4 trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided in 3 groups: patients with chronic total occlusions (CTO), patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5-years were analyzed. Of 5,487 patients treated with R-ZES in these trials, 8.0% had CTO's, 8.5% rec-TO's and 83.5% non-TO's. Patients had a mean age of 62.8 years, approximately 25% were female and 30% diabetics. TLF was similar in the 3 groups at 5 years (TLF was 13.2%, 12.5% and 13.3% in the CTO, rec-TO and non-TO groups, respectively, p=0.96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively, p=0.11).CONCLUSIONS: In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.
AB - AIMS: Reports of long-term outcomes of patients treated with drug-eluting stents in total coronary occlusions are limited. We analyzed clinical outcomes of patients treated with the zotarolimus-eluting Resolute stent (R-ZES) implanted in total coronary versus non-occluded lesions.METHODS AND RESULTS: Patients treated with R-ZES and included in 4 trials (RESOLUTE All Comers, RESOLUTE International, RESOLUTE China RCT, and RESOLUTE China Registry) were pooled and divided in 3 groups: patients with chronic total occlusions (CTO), patients with total occlusions that had occurred recently (rec-TO), and patients without total occlusions (non-TO). Clinical outcomes at 5-years were analyzed. Of 5,487 patients treated with R-ZES in these trials, 8.0% had CTO's, 8.5% rec-TO's and 83.5% non-TO's. Patients had a mean age of 62.8 years, approximately 25% were female and 30% diabetics. TLF was similar in the 3 groups at 5 years (TLF was 13.2%, 12.5% and 13.3% in the CTO, rec-TO and non-TO groups, respectively, p=0.96). Stent thrombosis tended to occur more frequently for rec-TO compared to CTO and non-TO patients (2.6% vs 1.2% and 1.3%, respectively, p=0.11).CONCLUSIONS: In this large population of patients who had R-ZES implanted, 5-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.
KW - Cardiovascular Agents
KW - China/epidemiology
KW - Coronary Artery Disease
KW - Coronary Occlusion/surgery
KW - Drug-Eluting Stents
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Myocardial Infarction
KW - Percutaneous Coronary Intervention/adverse effects
KW - Prosthesis Design
KW - Sirolimus/analogs & derivatives
KW - Time Factors
KW - Treatment Outcome
KW - Drug-eluting stent
KW - Stable angina
KW - Chronic coronary total occlusion
KW - ACS/NSTE-ACS
UR - http://www.scopus.com/inward/record.url?scp=85103473324&partnerID=8YFLogxK
U2 - 10.4244/EIJ-D-19-00866
DO - 10.4244/EIJ-D-19-00866
M3 - Journal article
C2 - 31746760
VL - 16
SP - 1326
EP - 1332
JO - EuroIntervention
JF - EuroIntervention
SN - 1774-024X
IS - 16
ER -